143
Views
0
CrossRef citations to date
0
Altmetric
Review

An Overview of the use and Misuse/Abuse of Opioid Analgesics in Different World Regions and Future Perspectives

ORCID Icon
Pages 535-555 | Received 01 Oct 2021, Accepted 11 Jan 2022, Published online: 04 Feb 2022

References

  • van Hecke O , TorranceN , SmithBH. Chronic pain epidemiology and its clinical relevance. Br. J. Anaesth.111(1), 13–18 (2013).
  • Schieber LZ , GuyGPJr , SethP , LosbyJL. Variation in adult outpatient opioid prescription dispensing by age and sex – United States, 2008–2018. MMWR Morb. Mortal. Wkly. Rep.69(11), 298–302 (2020).
  • Khademi H , KamangarF , BrennanP , MalekzadehR. Opioid therapy and its side effects: a review. Arch. Iran. Med.19(12), 870–876 (2016).
  • Volkow N , BenvenisteH , McLellanAT. Use and misuse of opioids in chronic pain. Annu. Rev. Med.69, 451–465 (2018).
  • Jones MR , ViswanathO , PeckJ , KayeAD , GillJS , SimopoulosTT. A brief history of the opioid epidemic and strategies for pain medicine. Pain Ther.7(1), 13–21 (2018).
  • Dhalla IA , PersaudN , JuurlinkDN. Facing up to the prescription opioid crisis. BMJ343, d5142 (2011).
  • Shipton EE , ShiptonAJ , WillimanJA , ShiptonEA. Deaths from opioid overdosing: implications of Coroners’ Inquest Reports 2008–2012 and annual rise in opioid prescription rates: a population-based cohort study. Pain Ther.6(2), 203–215 (2017).
  • OECD . Health at a Glance 2019: OECD Indicators, OECD Publishing, Paris, France (2019). https://doi.org/10.1787/4dd50c09-en
  • IASP . Classification of chronic pain, second edition, revised (2018). www.iasp-pain.org
  • Mills SEE , NicolsonKP , SmithBH. Chronic pain: a review of its epidemiology and associated factors in population-based studies. Br. J. Anaesth.123(2), e273–283 (2019).
  • Steingrímsdóttir ÓA , LandmarkT , MacfarlaneGJ , NielsenCS. Defining chronic pain in epidemiological studies: a systematic review and meta-analysis. Pain158(11), 2092–2107 (2017).
  • Breivik H , ChernyN , CollettBet al. Cancer-related pain: a pan-European survey of prevalence, treatment, and patient attitudes. Ann. Oncol.20(8), 1420–1433 (2009).
  • van den Beuken-van Everdingen MH , HochstenbachLM , JoostenEA , Tjan-HeijnenVC , JanssenDJ. Update on prevalence of pain in patients with cancer: systematic review and meta-analysis. J. Pain Symptom Manage.51(6), 1070–1090 (2016).
  • van Hecke O , AustinSK , KhanRA , SmithBH , TorranceN. Neuropathic pain in the general population: a systematic review of epidemiological studies. Pain155(4), 654–662 (2014).
  • Bouhassira D , Lantéri-MinetM , AttalN , LaurentB , TouboulC. Prevalence of chronic pain with neuropathic characteristics in the general population. Pain136(3), 380–387 (2008).
  • Dueñas M , OjedaB , SalazarA , MicoJA , FaildeI. A review of chronic pain impact on patients, their social environment and the health care system. J. Pain Res.9, 57–67 (2016).
  • Breivik H , CollettB , VentafriddaV , CohenR , GallacherD. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur. J. Pain10(4), 287–333 (2006).
  • Nahin RL . Estimates of pain prevalence and severity in adults: United States, 2012. J. Pain16(8), 769–780 (2015).
  • Fayaz A , CroftP , LangfordRM , DonaldsonLJ , JonesGT. Prevalence of chronic pain in the UK: a systematic review and meta-analysis of population studies. BMJ Open6(6), e010364 (2016).
  • Dahlhamer J , LucasJ , ZelayaCet al. Prevalence of chronic pain and high-impact chronic pain among adults - United States, 2016. MMWR Morb. Mortal. Wkly. Rep.67(36), 1001–1006 (2018).
  • Elliott AM , SmithBH , PennyKI , SmithWC , ChambersWA. The epidemiology of chronic pain in the community. Lancet354(9186), 1248–1252 (1999).
  • Smith BH , ElliottAM , ChambersWA , SmithWC , HannafordPC , PennyK. The impact of chronic pain in the community. Fam. Pract.18(3), 292–299 (2001).
  • Steinman MA , KomaikoKD , FungKZ , RitchieCS. Use of opioids and other analgesics by older adults in the United States, 1999–2010. Pain Med.16(2), 319–327 (2015).
  • Sandvik R , SelbaekG , KirkevoldO , AarslandD , HuseboBS. Analgesic prescribing patterns in Norwegian nursing homes from 2000 to 2011: trend analyses of four data samples. Age Ageing45(1), 54–60 (2016).
  • Kim KH , SeoHJ , AbdiS , HuhB. All about pain pharmacology: what pain physicians should know. Korean J. Pain33(2), 108–120 (2020).
  • WHO Collaborating Centre for Drug Statistics Methodology . ATC/DDD Index (2021). https://www.whocc.no/atc_ddd_index/?code=N02
  • World Health Organization . WHO guidelines for the pharmacological and radiotherapeutic management of cancer pain in adults and adolescents (2019). https://www.who.int/publications/i/item/9789241550390
  • IASP . IASP statement on opioids (2018). https://www.iasp-pain.org/Advocacy/OpioidPositionStatement
  • Fallon M , GiustiR , AielliFet al. Management of cancer pain in adult patients: ESMO Clinical Practice Guidelines. Ann. Oncol.29(Suppl. 4), iv166–iv191 (2018).
  • Bennett MI , EisenbergE , AhmedzaiSHet al. Standards for the management of cancer-related pain across Europe-A position paper from the EFIC Task Force on Cancer Pain. Eur. J. Pain23(4), 660–668 (2019).
  • Attal N . Pharmacological treatments of neuropathic pain: the latest recommendations. Rev. Neurol. (Paris)175(1–2), 46–50 (2019).
  • Bril V , EnglandJ , FranklinGMet al. Evidence-based guideline: Treatment of painful diabetic neuropathy: report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology76(20), 1758–1765 (2011).
  • Manchikanti L , KayeAM , KnezevicNNet al. Responsible, safe, and effective prescription of opioids for chronic non-cancer pain: American Society of Interventional Pain Physicians (ASIPP) Guidelines. Pain Physician20(2S), S3–S92 (2017).
  • O’Brien T , ChristrupLL , DrewesAMet al. European Pain Federation position paper on appropriate opioid use in chronic pain management. Eur. J. Pain21(1), 3–19 (2017).
  • Dowell D , HaegerichTM , ChouR. CDC guideline for prescribing opioids for chronic pain - United States, 2016. MMWR Recomm. Rep.65(1), 1–49 (2016).
  • Azadfard M , HueckerMR , LeamingJM. Opioid addiction. 2021 Aug 26. In: StatPearls.StatPearls Publishing, FL, USA (2021).
  • Trescot AM , DattaS , LeeM , HansenH. Opioid pharmacology. Pain Physician11(Suppl. 2), S133–153 (2008).
  • Alexander SP , DavenportAP , KellyEet al. The Concise Guide to PHARMACOLOGY 2015/16: G protein-coupled receptors. Br. J. Pharmacol.172(24), 5744–5869 (2015).
  • Mollereau C , MouledousL. Tissue distribution of the opioid receptor-like (ORL1) receptor. Peptides21(7), 907–917 (2000).
  • Al-Hasani R , BruchasMR. Molecular mechanisms of opioid receptor-dependent signaling and behavior. Anesthesiology115(6), 1363–1381 (2011).
  • Leppert W . Pain management in patients with cancer: focus on opioid analgesics. Curr. Pain Headache Rep.15(4), 271–279 (2011).
  • Franklin GM ; American Academy of Neurology. Opioids for chronic noncancer pain: a position paper of the American Academy of Neurology. Neurology83(14), 1277–1284 (2014).
  • Magarbeh L , GorbovskayaI , LeFoll B , JhiradR , MüllerDJ. Reviewing pharmacogenetics to advance precision medicine for opioids. Biomed. Pharmacother.142, 112060 (2021).
  • Cheatle MD . Prescription opioid misuse, abuse, morbidity, and mortality: balancing effective pain management and safety. Pain Med.16(Suppl. 1), S3–8 (2015).
  • Webster LR . Risk factors for opioid-use disorder and overdose. Anesth. Analg.125(5), 1741–1748 (2017).
  • Dolinak D . Opioid toxicity. Acad. Forensic Pathol.7(1), 19–35 (2017).
  • Higgins C , SmithBH , MatthewsK. Incidence of iatrogenic opioid dependence or abuse in patients with pain who were exposed to opioid analgesic therapy: a systematic review and meta-analysis. Br. J. Anaesth.120(6), 1335–1344 (2018).
  • Attal N , CruccuG , BaronRet al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur. J. Neurol.17(9), e1113–e1188 (2010).
  • Paice JA , PortenoyR , LacchettiCet al. Management of chronic pain in survivors of adult cancers: American Society of Clinical Oncology Clinical Practice Guideline. J. Clin. Oncol.34(27), 3325–3345 (2016).
  • Brownstein MJ . A brief history of opiates, opioid peptides, and opioid receptors. Proc. Natl Acad. Sci. USA90(12), 5391–5393 (1993).
  • Quinlan J , RannS , BastableR , LevyN. Perioperative opioid use and misuse. Clin. Med. (Lond).19(6), 441–445 (2019).
  • Ballantyne JC , KalsoE , StannardC. WHO analgesic ladder: a good concept gone astray. BMJ352, i20 (2016).
  • Amer M , BeadVR , BathonJ , BlumenthalRS , EdwardsDN. Use of nonsteroidal anti-inflammatory drugs in patients with cardiovascular disease: a cautionary tale. Cardiol. Rev.18(4), 204–212 (2010).
  • Bernard SA , ChelminskiPR , IvesTJ , RanapurwalaSI. Management of pain in the United States-a brief history and implications for the opioid epidemic. Health Serv. Insights11, 1178632918819440 (2018).
  • [No authors listed]. Quality improvement guidelines for the treatment of acute pain and cancer pain. American Pain Society Quality of Care Committee. JAMA274(23), 1874–1880 (1995).
  • Brennan F , CarrD , CousinsM. Access to pain management-still very much a human right. Pain Med.17(10), 1785–1789 (2016).
  • Manchikanti L , HelmS2nd , FellowsBet al. Opioid epidemic in the United States. Pain Physician15(Suppl. 3), ES9–38 (2012).
  • Lutz M . Metamizole (dipyrone) and the liver: a review of the literature. J. Clin. Pharmacol.59(11), 1433–1442 (2019).
  • Daubresse M , ChangHY , YuYet al. Ambulatory diagnosis and treatment of nonmalignant pain in the United States, 2000–2010. Med. Care51(10), 870–878 (2013).
  • Burgess HJ , SiddiquiA , BurgessFW. Long-term opioid therapy for chronic pain and the risk of opioid addiction. R. I. Med. J. (2013)97(10), 25–28 (2014).
  • Kotecha MK , SitesBD. Pain policy and abuse of prescription opioids in the USA: a cautionary tale for Europe. Anaesthesia68(12), 1210–1215 (2013).
  • OECD . Addressing Problematic Opioid Use in OECD Countries, OECD Health Policy Studies, OECD Publishing, Paris, France (2019). https://doi.org/10.1787/a18286f0-en
  • Levy B , PaulozziL , MackKA , JonesCM. Trends in opioid analgesic-prescribing rates by specialty, U.S., 2007–2012. Am. J. Prev. Med.49(3), 409–413 (2015).
  • Centers for Disease Control and Prevention . Opioid basics. Understanding the epidemic. Page last reviewed: 17 March 2021. https://www.cdc.gov/opioids/basics/epidemic.html
  • Verhamme KMC , BohnenAM. Are we facing an opioid crisis in Europe?Lancet Public Health4(10), e483–e484 (2019).
  • Jacob L , KostevK. Prevalence of pain medication prescriptions in France, Germany, and the UK - a cross-sectional study including 4,270,142 patients. Postgrad. Med.130(1), 32–36 (2018).
  • La Frenais FL , BedderR , VickerstaffV , StoneP , SampsonEL. Temporal trends in analgesic use in long-term care facilities: a systematic review of international prescribing. J. Am. Geriatr. Soc.66(2), 376–382 (2018).
  • Stokes A , BerryKM , HempsteadK , LundbergDJ , NeogiT. Trends in prescription analgesic use among adults with musculoskeletal conditions in the United States, 1999–2016. JAMA Netw. Open2(12), e1917228 (2019).
  • Berterame S , ErthalJ , ThomasJet al. Use of and barriers to access to opioid analgesics: a worldwide, regional, and national study. Lancet387(10028), 1644–1656 (2016).
  • Peacock A , LeungJ , LarneySet al. Global statistics on alcohol, tobacco and illicit drug use: 2017 status report. Addiction113(10), 1905–1926 (2018).
  • Degenhardt L , GrebelyJ , StoneJet al. Global patterns of opioid use and dependence: harms to populations, interventions, and future action. Lancet394(10208), 1560–1579 (2019).
  • Drug and Alcohol Research Connections . Majority of opioid overdose deaths in Australia are related to pharmaceutical opioids (2018). http://www.connections.edu.au/news/majority-opioid-overdose-deaths-australia-are-related-pharmaceutical-opioids#
  • GBD 2018 Alcohol and Drug Use Collaborators . The global burden of disease attributable to alcohol and drug use in 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Psychiatry5(12), 987–1012 (2018).
  • GBD 2017 Disease and Injury Incidence and Prevalence Collaborators . Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet.392(10159), 1789–1858 (2018).
  • Guy GP Jr , ZhangK , BohmMKet al. Vital signs: changes in opioid prescribing in the United States, 2006–2015. MMWR. Morb. Mortal. Wkly. Rep.66(26), 697–704 (2017).
  • Vijay A , RheeTG , RossJS. U.S. prescribing trends of fentanyl, opioids, and other pain medications in outpatient and emergency department visits from 2006 to 2015. Prev. Med.123, 123–129 (2019).
  • Han B , ComptonWM , BlancoC , CraneE , LeeJ , JonesCM. prescription opioid use, misuse, and use disorders in U.S. adults: 2015 National Survey on Drug Use and Health. Ann. Intern. Med.167(5), 293–301 (2017).
  • Bigal LM , BibeauK , DunbarS. Tramadol prescription over a 4-year period in the USA. Curr. Pain Headache Rep.23(10), 76 (2019).
  • Keshwani S , GrandeI , MaguireM , GoodinA , VouriSM , Hincapie-CastilloJM. Trends in use of prescription nonsteroidal anti-inflammatory medications before vs after implementation of a Florida law restricting opioid prescribing for acute pain. JAMA Netw. Open4(6), e2113383 (2021).
  • Fassio V , AspinallSL , ZhaoXet al. Trends in opioid and nonsteroidal anti-inflammatory use and adverse events. Am. J. Manag. Care24(3), e61–e72 (2018).
  • Hudgins JD , PorterJJ , MonuteauxMC , BourgeoisFT. Prescription opioid use and misuse among adolescents and young adults in the United States: a national survey study. PLoS Med.16(11), e1002922 (2019).
  • Wilson N , KariisaM , SethP , SmithH4th , DavisNL. Drug and opioid-involved overdose deaths - United States, 2017–2018. MMWR. Morb. Mortal. Wkly. Rep.69(11), 290–297 (2020).
  • Belzak L , HalversonJ. The opioid crisis in Canada: a national perspective. Health Promot. Chronic Dis. Prev. Can.38(6), 224–233 (2018).
  • Barbera L , SutradharR , ChuAet al. Opioid prescribing among cancer and non-cancer patients: time trend analysis in the elderly using administrative data. J. Pain Symptom Manage.54(4), 484–492.e1 (2017).
  • Fischer B , JonesW , VojtilaL , KurdyakP. Patterns, changes, and trends in prescription opioid dispensing in Canada, 2005–2016. Pain Physician21(3), 219–228 (2018).
  • Health Canada . Canadian Tobacco, Alcohol and Drugs Survey (CTADS): summary of results for 2017 (2021). https://www.canada.ca/en/health-canada/services/canadian-tobacco-alcohol-drugs-survey/2017-summary.html#n3
  • Public Health Agency of Canada - Special Advisory Committee on the Epidemic of Opioid Overdoses . Opioid-related harms in Canada. Public Health Agency of Canada, Ottawa, Canada (2020). https://health-infobase.canada.ca/substance-related-harms/opioids
  • Gomes T , KhuuW , MartinsDet al. Contributions of prescribed and non-prescribed opioids to opioid related deaths: population based cohort study in Ontario, Canada. BMJ362, k3207 (2018).
  • Bosetti C , SantucciC , RadrezzaS , ErthalJ , BerterameS , CorliO. Trends in the consumption of opioids for the treatment of severe pain in Europe, 1990–2016. Eur. J. Pain23(4), 697–707 (2019).
  • Helmerhorst GT , TeunisT , JanssenSJ , RingD. An epidemic of the use, misuse and overdose of opioids and deaths due to overdose, in the United States and Canada: is Europe next?Bone Joint J.99-B(7), 856–864 (2017).
  • van Amsterdam J , vanden Brink W. The misuse of prescription opioids: a threat for Europe?Curr. Drug Abuse Rev.8(1), 3–14 (2015).
  • European Monitoring Centre for Drugs and Drug Addiction . European Drug Report 2019: trends and developments. Publications Office of the European Union, Luxembourg (2019).
  • Macfarlane GJ , BeasleyM , JonesGT , StannardC. The epidemiology of regular opioid use and its association with mortality: Prospective cohort study of 466 486 UK biobank participants. EClinicalMedicine21, 100321 (2020).
  • Curtis HJ , CrokerR , WalkerAJ , RichardsGC , QuinlanJ , GoldacreB. Opioid prescribing trends and geographical variation in England, 1998–2018: a retrospective database study. Lancet Psychiatry6(2), 140–150 (2019).
  • Davies E , PhillipsC , RanceJ , SewellB. Examining patterns in opioid prescribing for non-cancer-related pain in Wales: preliminary data from a retrospective cross-sectional study using large datasets. Br. J. Pain13(3), 145–158 (2019).
  • Mordecai L , ReynoldsC , DonaldsonLJ , WilliamsAC. Patterns of regional variation of opioid prescribing in primary care in England: a retrospective observational study. Br. J. Gen. Pract.68(668), e225–e233 (2018).
  • Zin CS , ChenLC , KnaggsRD. Changes in trends and pattern of strong opioid prescribing in primary care. Eur. J. Pain18(9), 1343–1351 (2014).
  • Torrance N , MansoorR , WangHet al. Association of opioid prescribing practices with chronic pain and benzodiazepine co-prescription: a primary care data linkage study. Br. J. Anaesth.120(6), 1345–1355 (2018).
  • Ashaye T , HounsomeN , CarnesDet al. Opioid prescribing for chronic musculoskeletal pain in UK primary care: results from a cohort analysis of the COPERS trial. BMJ Open8(6), e019491 (2018).
  • Cooper AJM , WillisJ , FullerJet al. Prevalence and incidence trends for diagnosed prescription opioid use disorders in the United Kingdom. Pain Ther.6(1), 73–84 (2017).
  • Jarlbaek L . Opioid prescribing habits differ between Denmark, Sweden and Norway - and they change over time. Scand. J. Pain19(3), 491–499 (2019).
  • Muller AE , ClausenT , SjøgrenP , OdsbuI , SkurtveitS. Prescribed opioid analgesic use developments in three Nordic countries, 2006–2017. Scand. J. Pain19(2), 345–353 (2019).
  • Neutel CI , SkurtveitS , BergC , SakshaugS. Trends in prescription of strong opioids for 41–80 year old Norwegians, 2005–2010. Eur. J. Pain18(3), 438–446 (2014).
  • Skurtveit S , FuruK , BorchgrevinkP , HandalM , FredheimO. To what extent does a cohort of new users of weak opioids develop persistent or probable problematic opioid use?Pain152(7), 1555–1561 (2011).
  • Fugelstad A , ThiblinI , JohanssonLA , ÅgrenG , SidorchukA. Opioid-related deaths and previous care for drug use and pain relief in Sweden. Drug Alcohol Depend.201, 253–259 (2019).
  • Rosner B , NeicunJ , YangJC , Roman-UrrestarazuA. Opioid prescription patterns in Germany and the global opioid epidemic: systematic review of available evidence. PLoS One14(8), e0221153 (2019).
  • Marschall U , L’hoestH , RadbruchL , HäuserW. Long-term opioid therapy for chronic non-cancer pain in Germany. Eur. J. Pain20(5), 767–776 (2016).
  • Häuser W , SchubertT , ScherbaumN , TölleT. [Long-term opioid therapy of non-cancer pain: prevalence and predictors of hospitalization in the event of possible misuse]. Schmerz32(6), 419–426 (2018).
  • Wagemaakers FN , HollingworthSA , Kreijkamp-KaspersS , TeeEHL , LeendertseAJ , van DrielML. Opioid analgesic use in Australia and The Netherlands: a cross-country comparison. Int. J. Clin. Pharm.39(4), 874–880 (2017).
  • Kalkman GA , KramersC , van DongenRT , vanden Brink W , SchellekensA. Trends in use and misuse of opioids in the Netherlands: a retrospective, multi-source database study. Lancet Public Health4(10), e498–e505 (2019).
  • Chenaf C , KaboréJL , DelormeJet al. Prescription opioid analgesic use in France: trends and impact on morbidity-mortality. Eur. J. Pain23(1), 124–134 (2019).
  • Garcia del Pozo J , CarvajalA , ViloriaJM , VelascoA , Garciadel Pozo V. Trends in the consumption of opioid analgesics in Spain. Higher increases as fentanyl replaces morphine. Eur. J. Clin. Pharmacol.64(4), 411–415 (2008).
  • Ruiz-López D , Alonso-BabarroA. Opioid consumption in the Community of Madrid (Spain) between 2004 and 2014. Rev. Clin. Esp.219(7), 367–374 (2019).
  • Uusküla A , TaluA , VorobjovSet al. The fentanyl epidemic in Estonia: factors in its evolution and opportunities for a comprehensive public health response, a scoping review. Int. J. Drug Policy81, 102757 (2020).
  • Islam MM , McRaeIS , MazumdarS , TaplinS , McKetinR. Prescription opioid analgesics for pain management in Australia: 20 years of dispensing. Intern. Med. J.46(8), 955–963 (2016).
  • Karanges EA , BuckleyNA , BrettJet al. Trends in opioid utilisation in Australia, 2006–2015: insights from multiple metrics. Pharmacoepidemiol. Drug Saf.27(5), 504–512 (2018).
  • Islam MM , WollersheimD. Who are dispensed the bulk amount of prescription opioids?J. Clin. Med.8(3), 293 (2019).
  • Campbell G , NielsenS , LaranceBet al. Pharmaceutical opioid use and dependence among people living with chronic pain: associations observed within the pain and opioids in treatment (POINT) cohort. Pain Med.16(9), 1745–1758 (2015).
  • Blanch B , PearsonSA , HaberPS. An overview of the patterns of prescription opioid use, costs and related harms in Australia. Br. J. Clin. Pharmacol.78(5), 1159–1166 (2014).
  • Roxburgh A , HallWD , DobbinsTet al. Trends in heroin and pharmaceutical opioid overdose deaths in Australia. Drug Alcohol Depend.179, 291–298 (2017).
  • Berecki-Gisolf J , Hassani-MahmooeiB , ClappertonA , McClureR. Prescription opioid dispensing and prescription opioid poisoning: Population data from Victoria, Australia 2006 to 2013. Aust. N. Z. J. Public Health41(1), 85–91 (2017).
  • Hopkins RE , DobbinM , PilgrimJL. Unintentional mortality associated with paracetamol and codeine preparations, with and without doxylamine, in Australia. Forensic Sci. Int.282, 122–126 (2018).
  • Cairns R , SchafferAL , BrownJA , PearsonSA , BuckleyNA. Codeine use and harms in Australia: evaluating the effects of re-scheduling. Addiction115(3), 451–459 (2020).
  • Elphinston RA , ConnorJP , de AndradeDet al. Impact of a policy change restricting access to codeine on prescription opioid-related emergency department presentations: an interrupted time series analysis. Pain162(4), 1095–1103 (2021).
  • Shipton EA , ShiptonEE , ShiptonAJ. A review of the opioid epidemic: what do we do about it?Pain Ther.7(1), 23–36 (2018).
  • Ministry of Justice . Narcotics and Psychotropics Control Act, Act No. 14 of March 17, 1953. Amendment of Act No. 50 of 2015 (2021). http://www.japaneselawtranslation.go.jp/law/detail/?id=2849&vm=04re=02
  • Onishi E , KobayashiT , DexterE , MarinoM , MaenoT , DeyoRA. Comparison of opioid prescribing patterns in the United States and Japan: primary care physicians’ attitudes and perceptions. J. Am. Board Fam. Med.30(2), 248–254 (2017).
  • Tannoury C , KlewenoC , KamathAF , GaryJ. Comparison of opioid use and prescribing patterns in orthopedic surgery in Japan and the United States: A JOA-AOA Traveling Fellowship Investigation. J. Orthop. Sci.25, 520–524 (2020).
  • Oh TK , JeonYT , ChoiJW. Trends in chronic opioid use and association with five-year survival in South Korea: a population-based cohort study. Br. J. Anaesth.123(5), 655–663 (2019).
  • Fang W , LiuT , GuZ , LiQ , LuoC. Consumption trend and prescription pattern of opioid analgesics in China from 2006 to 2015. Eur. J. Hosp. Pharm.26(3), 140–145 (2019).
  • Onwuchekwa Uba R , Ankoma-DarkoK , ParkSK. International comparison of mitigation strategies for addressing opioid misuse: A systematic review. J. Am. Pharm. Assoc. (2003)60(1), 195–204 (2020).
  • Ayoo K , MikhaeilJ , HuangA , WąsowiczM. The opioid crisis in North America: facts and future lessons for Europe. Anaesthesiol. Intensive Ther.52(2), 139–147 (2020).
  • Alexander GC , BallreichJ , MansourO , DowdyDW. Effect of reductions in opioid prescribing on opioid use disorder and fatal overdose in the United States: a dynamic Markov model. Addiction doi:10.1111/add.15698 (2021) ( Epub ahead of print).
  • Chen Q , LarochelleMR , WeaverDTet al. Prevention of prescription opioid misuse and projected overdose deaths in the United States. JAMA Netw. Open.2(2), e187621 (2019).
  • Soelberg CD , BrownREJr , DuVivier D , MeyerJE , RamachandranBK. The US opioid crisis: current federal and state legal issues. Anesth. Analg.125(5), 1675–1681 (2017).
  • CDC Newsroom. CDC advises against misapplication of the guideline for prescribing opioids for chronic pain (2021). https://www.cdc.gov/media/releases/2019/s0424-advises-misapplication-guideline-prescribing-opioids.html
  • Manchikanti L , SanapatiJ , BenyaminRM , AtluriS , KayeAD , HirschJA. Reframing the prevention strategies of the opioid crisis: focusing on prescription opioids, fentanyl, and heroin epidemic. Pain Phys.21(4), 309–326 (2018).
  • Kraus M , LintzerisN , BhaskarAet al. Consensus and controversies between pain and addiction experts on the prevention, diagnosis, and management of prescription opioid use disorder. J. Addict. Med.14(1), 1–11 (2020).
  • Alho H , DematteisM , LemboD , MaremmaniI , RonceroC , SomainiL. Opioid-related deaths in Europe: strategies for a comprehensive approach to address a major public health concern. Int. J. Drug Policy76, 102616 (2020).
  • Häuser W , MorlionB , VowlesKEet al. European clinical practice recommendations on opioids for chronic noncancer pain – Part 1: role of opioids in the management of chronic noncancer pain. Eur. J. Pain25(5), 949–968 (2021).
  • Krčevski Škvarč N , MorlionB , VowlesKEet al. European clinical practice recommendations on opioids for chronic noncancer pain – Part 2: Special situations. Eur. J. Pain25(5), 969–985 (2021).
  • Moisset X , TrouvinAP , TranVTet al. [Use of strong opioids in chronic non-cancer pain in adults. Evidence-based recommendations from the French Society for the Study and Treatment of Pain]. Presse Med.45(4 Pt 1), 447–462 (2016).
  • European Federation of Pharmaceutical Industries and Associations . The EFPIA Code of Practice (2019). https://www.efpia.eu/media/554639/efpia-code-report-2019.pdf
  • Bolliger L , StevensH. From opioid pain management to opioid crisis in the USA: how can public-private partnerships help?Front. Med. (Lausanne)6, 106 (2019).
  • Volkow ND , McLellanAT. Opioid abuse in chronic pain–misconceptions and mitigation strategies. N. Engl. J. Med.374(13), 1253–1263 (2016).
  • Kress HG , AldingtonD , AlonEet al. A holistic approach to chronic pain management that involves all stakeholders: change is needed. Curr. Med. Res. Opin.31(9), 1743–1754 (2015).
  • Patwardhan A , MatikaR , GordonJet al. Exploring the role of chronic pain clinics: potential for opioid reduction. Pain Physician21(6), E603–E610 (2018).
  • Volkow ND , CollinsFS. The role of science in addressing the opioid crisis. N. Engl. J. Med.377(4), 391–394 (2017).
  • D’Souza RS , LangM , EldrigeJS. Prescription drug monitoring program. 2021 Jul 12. In: StatPearls.StatPearls Publishing, FL, USA, (2021).
  • Gadd S , CoxN , SamuelsonJ , KenneyA , TurnerK , CochranG. Abuse-deterrent opioid formulations and the opioid crisis: a pharmacist’s perspective. Ther. Drug. Monit.43(1), 35–41 (2021).
  • Rauck RL . Mitigation of IV abuse through the use of abuse-deterrent opioid formulations: an overview of current technologies. Pain Pract.19(4), 443–454 (2019).
  • Litman RS , PagánOH , CiceroTJ. Abuse-deterrent opioid formulations. Anesthesiology128(5), 1015–1026 (2018).
  • Ehrlich AT , KiefferBL , DarcqE. Current strategies toward safer mu opioid receptor drugs for pain management. Expert Opin. Ther. Targets23(4), 315–326 (2019).
  • Gan TJ , WaseL. Oliceridine, a G protein-selective ligand at the μ-opioid receptor, for the management of moderate to severe acute pain. Drugs Today (Barc.)56(4), 269–286 (2020).
  • Lagard C , ChevillardL , GuillemynKet al. Bifunctional peptide-based opioid agonist/nociceptin antagonist ligand for dual treatment of nociceptive and neuropathic pain. Pain158(5), 505–515 (2017).
  • Burford NT , TraynorJR , AltA. Positive allosteric modulators of the μ-opioid receptor: a novel approach for future pain medications. Br. J. Pharmacol.172(2), 277–286 (2015).
  • Spahn V , DelVecchio G , LabuzDet al. A nontoxic pain killer designed by modeling of pathological receptor conformations. Science355(6328), 966–969 (2017).
  • Günther T , DasguptaP , MannAet al. Targeting multiple opioid receptors - improved analgesics with reduced side effects? Br. J. Pharmacol. 175(14), 2857–2868 (2018).
  • Ciotu CI , FischerMJM. Novel analgesics with peripheral targets. Neurotherapeutics17, 784–825 (2020).
  • Hijma HJ , GroeneveldGJ. Analgesic drug development: proof-of-mechanism and proof-of-concept in early phase clinical studies. Med. Drug Discov.10, 100083 (2021).
  • Hill KP . Medical marijuana for treatment of chronic pain and other medical and psychiatric problems: a clinical review. JAMA313(24), 2474–2483 (2015).
  • Aviram J , Samuelly-LeichtagG. Efficacy of cannabis-based medicines for pain management: a systematic review and meta-analysis of randomized controlled trials. Pain Physician20(6), E755–E796 (2017).
  • Nugent SM , MorascoBJ , O’NeilMEet al. The effects of cannabis among adults with chronic pain and an overview of general harms: a systematic review. Ann. Intern. Med.167(5), 319–331 (2017).
  • Stockings E , CampbellG , HallWDet al. Cannabis and cannabinoids for the treatment of people with chronic noncancer pain conditions: a systematic review and meta-analysis of controlled and observational studies. Pain159(10), 1932–1954 (2018).
  • Mücke M , PhillipsT , RadbruchL , PetzkeF , HäuserW. Cannabis-based medicines for chronic neuropathic pain in adults. Cochrane Database Syst. Rev.3(3), CD012182 (2018).
  • Hill KP , PalastroMD , JohnsonB , DitreJW. Cannabis and pain: a clinical review. Cannabis Cannabinoid Res.2(1), 96–104 (2017).
  • Ueberall MA , EssnerU , Mueller-SchwefeGH. Effectiveness and tolerability of THC:CBD oromucosal spray as add-on measure in patients with severe chronic pain: analysis of 12-week open-label real-world data provided by the German Pain e-Registry. J. Pain Res.12, 1577–1604 (2019).
  • Lee G , GroveyB , FurnishT , WallaceM. Medical cannabis for neuropathic pain. Curr. Pain Headache Rep.22(1), 8 (2018).
  • Hill KP . Medical use of cannabis in 2019. JAMA.322(10), 974–975 (2019).
  • Romero-Sandoval EA , FinchamJE , KolanoAL , SharpeBN , Alvarado-VázquezPA. Cannabis for chronic pain: challenges and considerations. Pharmacotherapy38, 651–662 (2018).
  • Wang L , HongPJ , MayCet al. Medical cannabis or cannabinoids for chronic non-cancer and cancer related pain: a systematic review and meta-analysis of randomised clinical trials. BMJ374, n1034 (2021).
  • Busse JW , VankrunkelsvenP , ZengLIet al. Medical cannabis or cannabinoids for chronic pain: a clinical practice guideline. BMJ374, n2040 (2021).
  • Lucas P . Rationale for cannabis-based interventions in the opioid overdose crisis. Harm Reduct. J.14(1), 58 (2017).
  • Noori A , MiroshnychenkoA , ShergillYet al. Opioid-sparing effects of medical cannabis or cannabinoids for chronic pain: a systematic review and meta-analysis of randomised and observational studies. BMJ Open11(7), e047717 (2021).
  • Rodgers HM , LimSA , YowJet al. Dopamine D1 or D3 receptor modulators prevent morphine tolerance and reduce opioid withdrawal symptoms. Pharmacol. Biochem. Behav.194, 172935 (2020).
  • Emery EC , LuizAP , WoodJN. Nav1.7 and other voltage-gated sodium channels as drug targets for pain relief. Expert Opin. Ther. Targets20(8), 975–983 (2016).
  • Guedon J , WuS , ZhengXet al. Current gene therapy using viral vectors for chronic pain. Mol. Pain.11, 27 (2015).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.